Cargando…
Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients
Background: The purpose of our study was to characterize clinical features among brain metastasis (BM) patients who were long term survivors (LTS). Methods: We reviewed a registry of BM patients referred to our multidisciplinary BM clinic between 2006 and 2014 and identified 97 who lived ≥ 3 years f...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903267/ https://www.ncbi.nlm.nih.gov/pubmed/33477698 http://dx.doi.org/10.3390/curroncol28010054 |
_version_ | 1783654699652612096 |
---|---|
author | Dasgupta, Archya Co, Jayson Winter, Jeff Millar, Barbara-Ann Laperriere, Normand Tsang, Derek S. van Prooijen, Monique Damyanovich, Andrei Heaton, Robert Coolens, Catherine Bernstein, Mark Kongkham, Paul Zadeh, Gelareh Berlin, Alejandro Conrad, Tatiana Moraes, Fabio Y. Shultz, David B. |
author_facet | Dasgupta, Archya Co, Jayson Winter, Jeff Millar, Barbara-Ann Laperriere, Normand Tsang, Derek S. van Prooijen, Monique Damyanovich, Andrei Heaton, Robert Coolens, Catherine Bernstein, Mark Kongkham, Paul Zadeh, Gelareh Berlin, Alejandro Conrad, Tatiana Moraes, Fabio Y. Shultz, David B. |
author_sort | Dasgupta, Archya |
collection | PubMed |
description | Background: The purpose of our study was to characterize clinical features among brain metastasis (BM) patients who were long term survivors (LTS). Methods: We reviewed a registry of BM patients referred to our multidisciplinary BM clinic between 2006 and 2014 and identified 97 who lived ≥ 3 years following BM diagnosis. The clinical and treatment characteristics were obtained from a prospectively maintained database, and additional information was obtained through review of electronic medical records and radiologic images. Survival analyses were performed using the Kaplan-Meier method. Results: Median follow up for LTS was 67 months (range 36–181). Median age was 54 years, 65% had single BM, 39% had stable extracranial disease at the time of BM treatment, and brain was the first site of metastasis in 76%. Targetable mutations were present in 39% of patients and 66% received treatment with targeted-, hormonal-, or immuno-therapy. Brain surgery at the time of diagnosis was performed in 40% and stereotactic radiosurgery (SRS) or whole brain radiotherapy (alone or combination) in 52% and 56%, respectively. Following initial BM treatment, 5-year intracranial disease-free survival was 39%, and the cumulative incidence of symptomatic radio-necrosis was 16%. Five and ten-year overall survival was 72% and 26%, respectively. Conclusion: Most LTS were younger than 60 years old and had a single BM. Many received treatment with surgery or targeted, immune, or hormonal therapy. |
format | Online Article Text |
id | pubmed-7903267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79032672021-02-25 Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients Dasgupta, Archya Co, Jayson Winter, Jeff Millar, Barbara-Ann Laperriere, Normand Tsang, Derek S. van Prooijen, Monique Damyanovich, Andrei Heaton, Robert Coolens, Catherine Bernstein, Mark Kongkham, Paul Zadeh, Gelareh Berlin, Alejandro Conrad, Tatiana Moraes, Fabio Y. Shultz, David B. Curr Oncol Article Background: The purpose of our study was to characterize clinical features among brain metastasis (BM) patients who were long term survivors (LTS). Methods: We reviewed a registry of BM patients referred to our multidisciplinary BM clinic between 2006 and 2014 and identified 97 who lived ≥ 3 years following BM diagnosis. The clinical and treatment characteristics were obtained from a prospectively maintained database, and additional information was obtained through review of electronic medical records and radiologic images. Survival analyses were performed using the Kaplan-Meier method. Results: Median follow up for LTS was 67 months (range 36–181). Median age was 54 years, 65% had single BM, 39% had stable extracranial disease at the time of BM treatment, and brain was the first site of metastasis in 76%. Targetable mutations were present in 39% of patients and 66% received treatment with targeted-, hormonal-, or immuno-therapy. Brain surgery at the time of diagnosis was performed in 40% and stereotactic radiosurgery (SRS) or whole brain radiotherapy (alone or combination) in 52% and 56%, respectively. Following initial BM treatment, 5-year intracranial disease-free survival was 39%, and the cumulative incidence of symptomatic radio-necrosis was 16%. Five and ten-year overall survival was 72% and 26%, respectively. Conclusion: Most LTS were younger than 60 years old and had a single BM. Many received treatment with surgery or targeted, immune, or hormonal therapy. MDPI 2021-01-18 /pmc/articles/PMC7903267/ /pubmed/33477698 http://dx.doi.org/10.3390/curroncol28010054 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dasgupta, Archya Co, Jayson Winter, Jeff Millar, Barbara-Ann Laperriere, Normand Tsang, Derek S. van Prooijen, Monique Damyanovich, Andrei Heaton, Robert Coolens, Catherine Bernstein, Mark Kongkham, Paul Zadeh, Gelareh Berlin, Alejandro Conrad, Tatiana Moraes, Fabio Y. Shultz, David B. Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients |
title | Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients |
title_full | Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients |
title_fullStr | Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients |
title_full_unstemmed | Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients |
title_short | Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients |
title_sort | clinicopathologic and treatment features of long-term surviving brain metastasis patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903267/ https://www.ncbi.nlm.nih.gov/pubmed/33477698 http://dx.doi.org/10.3390/curroncol28010054 |
work_keys_str_mv | AT dasguptaarchya clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT cojayson clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT winterjeff clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT millarbarbaraann clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT laperrierenormand clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT tsangdereks clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT vanprooijenmonique clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT damyanovichandrei clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT heatonrobert clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT coolenscatherine clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT bernsteinmark clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT kongkhampaul clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT zadehgelareh clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT berlinalejandro clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT conradtatiana clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT moraesfabioy clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients AT shultzdavidb clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients |